SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Venus Remedies trades higher on the bourses

24 Dec 2013 Evaluate

Venus Remedies is currently trading at Rs. 255.00, up by 13.75 points or 5.70% from its previous closing of Rs. 241.25 on the BSE.

The scrip opened at Rs. 241.90 and has touched a high and low of Rs. 258.40 and Rs. 241.90 respectively. So far 39791 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 358.05 on 15-May-2013 and a 52 week low of Rs. 140.00 on 02-Aug-2013.

Last one week high and low of the scrip stood at Rs. 258.40 and Rs. 222.20 respectively. The current market cap of the company is Rs. 288.57 crore.

The promoters holding in the company stood at 43.99% while Institutions and Non-Institutions held 8.58% and 47.43% respectively.

Venus Remedies has received innovative 100 award for its novel research product ‘ELORES’, a drug designed to fight superbugs to which other antibiotics failed to respond to, at an award function organized by ‘Inc. India’, business magazine in Delhi.

This award is recognition for the company’s effort in the field of AMR. ELORES is a new product and in a very short span of time, it has done exceptionally good in the market.

Venus Remedies is a pharmaceutical manufacturing company. The company provides formulations in area of antibiotics and oncological therapeutics. The company has two manufacturing facilities located in India and Germany. It manufactures Oncological and Cefelosporine Injectable products.

 

Venus Remedies Share Price

1801.25 84.80 (4.94%)
12-Jun-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1807.25
Dr. Reddys Lab 1273.90
Cipla 1388.80
Zydus Lifesciences 1104.35
Lupin 2292.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: